The ATCC has now developed an EML4-ALK fusion NSCLC cell line (ATCC® CCL-185IGTM; www.atcc.org) that can be used to validate the detection of this rearrangement in patients with cancer to aid in forming a precise treatment plan. This evidence concerns the gene EML4 and non-small cell lung carcinoma.